PaxMedica Shares Triple After Positive Results for Possible

By Chris Wack PaxMedica shares tripled to $8.52 after the company saw positive results from research exploring the potential of low-dose suramin for autism...

Related Keywords

, Chris Wack , Clinical Global Impressions Improvement , Article Normal , Biotechnology Services , Pharmaceuticals , Healthcare Life Sciences , Biopharmaceuticals , Neurodevelopmental Disorders , Autism Spectrum Disorders , Political General News , Health , Medical Conditions , Mental Disorders , Synd , Paxmedica , Pxmd , Us70424c2035 , Political , General News , Healthcare , Life Sciences ,